床旁表观扩散系数测量在乳腺MRI中减少活检的诊断效能:临床验证
本研究在单中心连续240个乳腺MRI发现的BI-RADS 4或5类病灶中,回顾性验证A6702试验的ADC cutoff。应用最优cutoff(1.53×10-3 mm2/sec)可使活检减少15.8%,敏感度92.1%;保守cutoff(1.68×10-3 mm2/sec)敏感度95.2%,活检减少10.4%。肿块敏感度高于非肿块强化(100% vs 85.3%,P=.009)。
要点
- 应用A6702最优ADC cutoff(1.53×10-3 mm2/sec)可使乳腺MRI病灶活检减少15.8%,敏感度92.1%。
- 保守ADC cutoff(1.68×10-3 mm2/sec)敏感度95.2%,活检减少10.4%。
- 肿块敏感度100%高于非肿块强化85.3%(P=.009),后者可能降低对原位及微浸润癌的敏感度。
核心结论
- 本研究验证了ADC cutoff在临床中可减少最多16%的MRI提示活检,但作者指出以非肿块强化表现的原位及微浸润病变敏感度可能降低作为代价。
研究设计与样本
- 单中心回顾性研究,连续纳入2015年5月至2019年1月乳腺MRI显示活检证实的BI-RADS 4或5类病灶且无同侧癌的201例女性共240个病灶,以病理为参考标准;MRI包括轴位T2加权、扩散加权和动态对比增强序列,评估临床判读时采集的床旁ADC测量值。
诊断标准与关键数值
- 应用A6702最优ADC cutoff(1.53×10-3 mm2/sec)总体活检减少率15.8%(240个病灶中38个,95%CI 11.2–20.9),敏感度92.1%(63个病灶中58个,95%CI 82.4–97.4),浸润性癌敏感度97.2%(36个病灶中35个,95%CI 82.7–99.6);应用保守ADC cutoff(1.68×10-3 mm2/sec)敏感度95.2%(63个病灶中60个,95%CI 86.7–99.0),活检减少率10.4%(240个病灶中25个,95%CI 6.7–14.5);筛查与诊断检查间敏感度无显著差异(P=.92和P=.40);肿块敏感度100%高于非肿块强化85.3%(P=.009)。
临床应用与阅片要点
- 作者指出该研究验证了ADC cutoff在临床中可减少最多16%的MRI提示活检,并提示以非肿块强化表现的原位及微浸润病变敏感度可能降低的代价。
局限性
- 作者指出以非肿块强化表现的原位及微浸润病变敏感度可能降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group multicenter A6702 trial identified an optimal apparent diffusion coefficient (ADC) cutoff to potentially reduce biopsies by 21% without affecting sensitivity. Whether this performance can be achieved in clinical settings has not yet been established. Purpose To validate the performance of point-of-care ADC measurements with the A6702 trial ADC cutoff for reducing unnecessary biopsies in lesions detected at breast MRI. Materials and Methods Consecutive breast MRI examinations performed from May 2015 to January 2019 at a single medical center and showing biopsy-confirmed Breast Imaging Reporting and Data System category 4 or 5 lesions, without ipsilateral cancer, were identified. Point-of-care lesion ADC measurements collected at clinical interpretation were retrospectively evaluated. MRI examinations included axial T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences. Sensitivity and biopsy reduction rates were calculated by applying the A6702 optimal (ADC, 1.53 × 10-3 mm2/sec) and alternate conservative (1.68 × 10-3 mm2/sec) cutoffs. Lesion pathologic outcomes were the reference standard. To assess reproducibility, one radiologist repeated ADC measurements, and agreement was summarized using the intraclass correlation coefficient. Results A total of 240 lesions in 201 women (mean age, 49 years ± 13 [SD]) with pathologic outcomes (63 malignant and 177 benign) were included. Applying the optimal ADC cutoff produced an overall biopsy reduction rate of 15.8% (38 of 240 lesions [95% CI: 11.2, 20.9]), with a sensitivity of 92.1% (58 of 63 lesions [95% CI: 82.4, 97.4]; sensitivity was 97.2% [35 of 36 lesions] [95% CI: 82.7, 99.6] for invasive cancers). Results were similar for screening versus diagnostic examinations (P = .92 and .40, respectively). Sensitivity was higher for masses than for nonmass enhancements (NMEs) (100% vs 85.3%; P = .009). Applying the conservative ADC cutoff achieved a sensitivity of 95.2% (60 of 63 lesions [95% CI: 86.7, 99.0]), with a biopsy reduction rate of 10.4% (25 of 240 lesions [95% CI: 6.7, 14.5]). Repeated single-reader measurements showed good agreement with clinical ADCs (intraclass correlation coefficient, 0.72 [95% CI: 0.58, 0.81]). Conclusion This study validated the clinical use of ADC cutoffs to reduce MRI-prompted biopsies by up to 16%, with a suggested tradeoff of lowered sensitivity for in situ and microinvasive disease manifesting as NME. Clinical trial registration no. NCT02022579 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Honda and Iima in this issue.
引用
- Youn I, Biswas D, Hippe DS, et al. Diagnostic Performance of Point-of-Care Apparent Diffusion Coefficient Measures to Reduce Biopsy in Breast Lesions at MRI: Clinical Validation. Radiology. 2024. PMID: 38349238. doi:10.1148/radiol.232313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。